137 related articles for article (PubMed ID: 37818704)
21. Clinical, biological, radiological, and genetic study of LPAC syndrome in Tunisian patients.
Halleb Y; Ben Jazia E; Akkari I; Zaghouani H; Hmila F; Ghrissi R; Saad A; Gribaa M
Arab J Gastroenterol; 2022 Aug; 23(3):210-217. PubMed ID: 35922258
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
23. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
24. A homozygous ABCB4 mutation causing an LPAC syndrome evolves into cholangiocarcinoma.
Khabou B; Trigui A; Boudawara TS; Keskes L; Kamoun H; Barbu V; Fakhfakh F
Clin Chim Acta; 2019 Aug; 495():598-605. PubMed ID: 31181191
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
[TBL] [Abstract][Full Text] [Related]
26. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis.
Pasmant E; Goussard P; Baranes L; Laurendeau I; Quentin S; Ponsot P; Consigny Y; Farges O; Condat B; Vidaud D; Vidaud M; Chen JM; Parfait B
Eur J Hum Genet; 2012 Mar; 20(3):277-82. PubMed ID: 21989363
[TBL] [Abstract][Full Text] [Related]
27. UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3.
Zhou D; Kong L; Jiang Y; Wang C; Ni Y; Wang Y; Zhang H; Ruan J
Chem Biol Interact; 2019 Sep; 310():108745. PubMed ID: 31299240
[TBL] [Abstract][Full Text] [Related]
28. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
29. Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3.
Poupon R; Barbu V; Chamouard P; Wendum D; Rosmorduc O; Housset C
Liver Int; 2010 Feb; 30(2):327-31. PubMed ID: 19840255
[TBL] [Abstract][Full Text] [Related]
30. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
31. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
32. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
34. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
35. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
Stättermayer AF; Halilbasic E; Wrba F; Ferenci P; Trauner M
J Hepatol; 2020 Sep; 73(3):651-663. PubMed ID: 32376413
[TBL] [Abstract][Full Text] [Related]
36. Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones.
Meredith TJ; Williams GV; Maton PN; Murphy GM; Saxton HM; Dowling RH
Gut; 1982 May; 23(5):382-9. PubMed ID: 7076015
[TBL] [Abstract][Full Text] [Related]
37. Clinical studies on cheno- and ursodeoxycholic acid treatment for gallstone dissolution.
Iwamura K
Hepatogastroenterology; 1980 Feb; 27(1):26-34. PubMed ID: 7203354
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
[TBL] [Abstract][Full Text] [Related]
39. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients.
Poupon R; Rosmorduc O; Boëlle PY; Chrétien Y; Corpechot C; Chazouillères O; Housset C; Barbu V
Hepatology; 2013 Sep; 58(3):1105-10. PubMed ID: 23533021
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
